In this regard, we now propose that stochastic dynamics of epigenetic switching suffices to dictate the emergence (and persistence) of tumor cell sub-populations with distinct degrees of responsiveness to EZH2 inhibitors in the absence of inactivating mutations of the EZH2 epigenetic partner KDM6A. This evidence concerns the gene EZH2 and neoplasm.